PRFX Stock Analysis: Buy, Sell, or Hold?
PRFX - PainReform Ltd. Ordinary Shares
$0.93
-0.02 (-2.13%)
âŧ
5d:
-4.77%
30d:
-4.56%
90d:
-33.09%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Jun 25, 2026
0d
Get Alerted When PRFX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PRFX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PRFX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: PRFX is currently trading at $0.93, which is considered slightly low relative to its 30-day fair value range of $0.92 to $1.00.
Technical Outlook: Technically, PRFX is in a downtrend. Immediate support is located at $0.90, while resistance sits at $1.09.
Market Sentiment: PRFX scores 21/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+1162.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PRFX is in a downtrend. Immediate support is located at $0.90, while resistance sits at $1.09.
Market Sentiment: PRFX scores 21/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+1162.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.92 -
$1.00
Company Quality Score
39/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (21/100)
- BULLISH: Trading 1162.8% below Wall St target ($12.00)
- WARNING: Composite score 38/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.92 -
$1.00
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.90
Resistance Level
$1.09
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Wall Street Target
$12.00
(+1162.8%)
Share & Embed Analysis
Last updated: October 02, 2026 3:15 PM ET
Data refreshes hourly during market hours. Next update: 4:15 PM
Data refreshes hourly during market hours. Next update: 4:15 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRFX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
BCRX
BioCryst PharmaceuticalsâĻ |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
